Table 2 Antifungal susceptibility of Candida bloodstream isolates in patients during the study period
| Â | Fluconazole | Itraconazole | Ketoconazole | Voriconazole | ||||
|---|---|---|---|---|---|---|---|---|
Species | No. of isolates tested | %S# | No. of isolates tested | %S | No. of isolates tested | %S | No. of isolates tested | %S |
C. albicans | 31 | 23 (74.2) | 31 | 29 (93.6) | 6 | 3 (50.0) | 22 | 22 (100.0) |
C. parapsilosis | 26 | 15 (57.7) | 26 | 25 (96.2) | 2 | 1 (50.0) | 22 | 22 (100.0) |
C. glabrata | 11 | 1 (9.1) | 11 | 1 (9.1) | 1 | 0 (0) | 5 | 5 (100.0) |
C. tropicalis | 38 | 12 (31.6) | 38 | 25 (65.8) | 5 | 0 (0) | 23 | 21 (91.3) |
C. krusei | 3 | 0 (0) | 3 | 1 (33.3) | 1 | 0 (0) | 3 | 3 (100.0) |
C. guilliermondii | 6 | 4 (66.7) | 6 | 5 (83.3) | 0 | 0 (0) | 5 | 5 (100.0) |
Other* | 16 | 4 (25.0) | 16 | 5 (31.3) | 3 | 3 (100.0) | 12 | 12 (100.0) |
Total | 128 | 59 (46.1) | 131 | 91 (69.5)* | 18 | 7 (38.9) | 92 | 90 (97.8) |